45 days later, BioCryst abandons another program, citing stiff competition

45 days later, BioCryst abandons another program, citing stiff competition

Source: 
Fierce Biotech
snippet: 

Last month, BioCryst trimmed down its pipeline to two drugs in complement-mediated diseases: BCX9930 and BCX10013. Fast-forward 45 days and BCX9930 is headed to the garbage can, too.